Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06879379 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

KPD Consolidation After ASCT in NDMM Patients

Name: KPD Consolidation After ASCT in NDMM Patients — clinical trial record (NCT06879379)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2/3

SponsorPeking University People's Hospital

Started2025-03

View on ClinicalTrials.gov ↗

Peking University People's Hospital

220 trials monitored

See 6 trials at risk

Multiple Myeloma

1,228 trials monitored

See 75 trials at risk

This study aims to evaluate the efficacy and safety of post-transplant consolidation therapy with the KPD regimen (carfilzomib, pomalidomide, and dexamethasone) versus no consolidation, followed by maintenance therapy, in patients with transplant-eligible newly diagnosed multiple myeloma (TE-NDMM). The primary goal is to compare minimal residual disease (MRD) negativity rates and overall treatment outcomes between the two groups.

Trial Details

NCT Number	NCT06879379
Lead Sponsor	Peking University People's Hospital
Conditions	Multiple Myeloma, Newly Diagnosed
Enrollment	202 participants
Start Date	2025-03
Primary Completion	2028-03 (estimated)
Study Completion	2029-03 (estimated)
Updated on ClinicalTrials.gov	2025-03-17